Alzheimer's disease and age-related memory decline (preclinical)

被引:67
|
作者
Terry, Alvin V., Jr. [1 ]
Callahan, Patrick M. [1 ]
Hall, Brandon [1 ]
Webster, Scott J. [1 ]
机构
[1] Med Coll Georgia, Dept Pharmacol & Toxicol & Small Anim Behav Core, Augusta, GA 30912 USA
关键词
Cognition; Drug development; Pro-cognitive; Neurotransmitter receptors; Mild Cognitive Impairment; Dementia; HISTAMINE H-3 RECEPTOR; NICOTINIC ACETYLCHOLINE-RECEPTOR; LONG-TERM POTENTIATION; OBJECT RECOGNITION MEMORY; 3-MORPHOLINO ARECOLINE DERIVATIVES; DELAYED MATCHING PERFORMANCE; CHOLINERGIC CHANNEL MODULATOR; MONOAMINE-OXIDASE INHIBITOR; PASSIVE-AVOIDANCE RESPONSE; MILD COGNITIVE IMPAIRMENT;
D O I
10.1016/j.pbb.2011.02.002
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer's disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as "Mild Cognitive Impairment" (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD and MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy and adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:190 / 210
页数:21
相关论文
共 50 条
  • [1] Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
    Celsis, P
    [J]. ANNALS OF MEDICINE, 2000, 32 (01) : 6 - 14
  • [2] Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease
    Harrington, Karra D.
    Schembri, Adrian
    Lim, Yen Ying
    Dang, Christa
    Ames, David
    Hassenstab, Jason
    Laws, Simon M.
    Rainey-Smith, Stephanie
    Robertson, Joanne
    Rowe, Christopher C.
    Sohrabi, Hamid R.
    Salvado, Olivier
    Weinborn, Michael
    Villemagne, Victor L.
    Masters, Colin L.
    Maruff, Paul
    [J]. NEUROBIOLOGY OF AGING, 2018, 70 : 170 - 179
  • [3] Age-related neuropathology, cognitive decline, and Alzheimer's disease
    Keller, JN
    [J]. AGEING RESEARCH REVIEWS, 2006, 5 (01) : 1 - 13
  • [4] Cardiorespiratory Fitness Mitigates Age-Related Brain Atrophy And Cognitive Decline In Preclinical Alzheimer's Disease
    Dougherty, Ryan J.
    Jonaitis, Erin
    Johnson, Sterling
    Okonkwo, Ozioma
    Cook, Dane B.
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2021, 53 (08): : 335 - 335
  • [5] Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease
    Hullinger, Rikki
    Puglielli, Luigi
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2017, 322 : 191 - 205
  • [6] Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline
    Hohman, Timothy J.
    Tommet, Doug
    Marks, Shawn
    Contreras, Joey
    Jones, Rich
    Mungas, Dan
    [J]. NEUROBIOLOGY OF AGING, 2017, 58 : 120 - 128
  • [7] The influence of preclinical Alzheimer's disease on age-related cognitive differences in very old age
    Jonsson, EH
    Bäckman, L
    Wahlin, Å
    [J]. INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2000, 35 (3-4) : 366 - 366
  • [8] APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
    Lim, Yen Ying
    Villemagne, Victor L.
    Pietrzak, Robert H.
    Ames, David
    Ellis, Kathryn A.
    Harrington, Karra
    Snyder, Peter J.
    Martins, Ralph N.
    Masters, Colin L.
    Rowe, Christopher C.
    Maruff, Paul
    [J]. NEUROBIOLOGY OF AGING, 2015, 36 (03) : 1239 - 1244
  • [9] DEVELOPMENT OF SCREENING WEB SITES FOR ALZHEIMER'S AND AGE-RELATED MEMORY DECLINE: PROGRESS UPDATE
    Ashford, C. B.
    Hamrick, K.
    Rose, T. L.
    Kaib, S.
    Vogelman, J.
    Wetherell, A.
    Martin, R. J.
    Ashford, J.
    [J]. GERONTOLOGIST, 2012, 52 : 101 - 102
  • [10] Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer's disease
    McKee, Chloe G.
    Hoffos, Madison
    Vecchiarelli, Haley A.
    Tremblay, Marie-Eve
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14